Arcutis Biotherapeutics(US:ARQT) ZACKS·2025-10-31 15:38Company Performance - Arcutis Biotherapeutics, Inc. (ARQT) shares have increased by 17.3% over the past month and reached a new 52-week high of $27.08 [1] - The stock has gained 78.9% since the beginning of the year, outperforming the Zacks Medical sector's 4.3% gain and the Zacks Medical - Biomedical and Genetics industry's 12% return [1] Earnings and Revenue - The company has a strong record of positive earnings surprises, having beaten earnings consensus estimates in the last four quarters [2] - In the latest earnings report on October 28, 2025, Arcutis reported EPS of $0.06, surpassing the consensus estimate of -$0.1, and beat the revenue estimate by 12.32% [2] - For the current fiscal year, Arcutis is expected to post earnings of -$0.24 per share on revenues of $360.24 million, reflecting a 79.31% change in EPS and an 83.29% change in revenues [3] - For the next fiscal year, the expected earnings are $0.41 per share on revenues of $439.41 million, indicating a year-over-year change of 273.61% in EPS and 21.97% in revenues [3] Valuation Metrics - Arcutis has a Value Score of D, while its Growth and Momentum Scores are both A, resulting in a VGM Score of B [6] - The stock currently holds a Zacks Rank of 2 (Buy), supported by a solid earnings estimate revision trend [7][8] Industry Comparison - The Medical - Biomedical and Genetics industry is positioned in the top 39% of all industries, suggesting favorable conditions for both Arcutis and its peer, Exact Sciences Corporation (EXAS) [11] - Exact Sciences has a Zacks Rank of 1 (Strong Buy) and has shown strong earnings performance, beating consensus estimates by 1,200% [10]